About this Session:
Dermatology services across Europe are experiencing an unprecedented gap between the demand for care and the availability of specialists qualified to provide it. The incidence of high-risk skin cancers, including melanoma, has soared, yet the specialist workforce has been growing at a much slower rate. To make matters worse, a significant portion of specialist clinical time is spent in the triage step, ruling out cancer, rather than treating patients most in need.
Since 2020, the NHS has been deploying clinically-validated AI into skin cancer pathways to triage patients - identifying and discharging benign patients earlier and supporting significant improvements in dermatology team efficiency and productivity, driving earlier detection and better patient outcomes. Six years since DERM, the only AI as a Medical Device authorised to make clinical decisions on the management of skin cancer, was first deployed, Skin Analytics CEO Neil Daly will share examples of how providers are using AI to autonomously discharge patients without review by a clinician in primary, acute, and at-home pathways.
Neil will show real-world examples and data of how AI is enabling dermatologists to focus their time and expertise on the most complex, high-risk cases, as well as patients on other pathways who would otherwise wait significantly longer for diagnosis and treatment. Neil will draw on the experiences of NHS Trusts and primary care teams - highlighting the impact the technology has had on capacity release, waiting list reduction and cost avoidance - as well as highlighting the benefit that DERM has already achieved for a major private insurer following implementation in early 2026.
Attendees will leave with a clear understanding of how AI is being deployed today, what advancements in the technology's ability - as well as unprecedented levels of regulatory certification that it continues to secure - mean for providers, insurers, and patients.
Speakers:
Neil Daly, CEO @ Skin Analytics
Helen Newble
Huw Penson